share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  11/20 06:01

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc. announced significant corporate changes in a recent Form 8-K filing with the SEC. On November 14, 2024, Simon Fry was appointed as a director of the company, effective December 18, 2024, after the annual meeting of stockholders. Fry brings over 35 years of investment banking experience to his new roles on the Audit and Compensation Committees. His initial compensation includes a stock option to purchase 420,000 shares of common stock. Additionally, on November 15, 2024, an amended employment agreement was executed with James Bligh, who will continue as the Interim Chief Financial Officer and Senior Vice President – Strategy. Bligh's agreement includes a £400,000 annual salary and up to a 40% discretionary cash bonus. The company also adopted an amendment to its bylaws, effective post the 2024 annual meeting, changing the quorum requirement for stockholder meetings from a majority to at least one-third of the voting power.
Conduit Pharmaceuticals Inc. announced significant corporate changes in a recent Form 8-K filing with the SEC. On November 14, 2024, Simon Fry was appointed as a director of the company, effective December 18, 2024, after the annual meeting of stockholders. Fry brings over 35 years of investment banking experience to his new roles on the Audit and Compensation Committees. His initial compensation includes a stock option to purchase 420,000 shares of common stock. Additionally, on November 15, 2024, an amended employment agreement was executed with James Bligh, who will continue as the Interim Chief Financial Officer and Senior Vice President – Strategy. Bligh's agreement includes a £400,000 annual salary and up to a 40% discretionary cash bonus. The company also adopted an amendment to its bylaws, effective post the 2024 annual meeting, changing the quorum requirement for stockholder meetings from a majority to at least one-third of the voting power.
Conduit Pharmaceuticals Inc.宣佈在最近提交給美國證券交易委員會的8-k表格中進行了重大企業變更。2024年11月14日,在股東年度大會後,西蒙·弗萊(Simon Fry)被任命爲該公司的董事,任職日期爲2024年12月18日。弗萊對他在審計和薪酬委員會上的新角色擁有超過35年的投資銀行經驗。他最初的補償包括一份購買42萬股普通股的期權。此外,於2024年11月15日,與詹姆斯·布萊(James Bligh)簽署了一份修訂後的僱傭協議,布萊將繼續擔任臨時首席財務官兼高級副總裁-策略。布萊的協議包括40萬英鎊的年薪和最高可達40%的自由現金獎金。該公司還通過了一項針對其章程的修正案,自2024年年度會議後生效,將股東會議的法定人數由多數改爲至少三分之一的表決權。
Conduit Pharmaceuticals Inc.宣佈在最近提交給美國證券交易委員會的8-k表格中進行了重大企業變更。2024年11月14日,在股東年度大會後,西蒙·弗萊(Simon Fry)被任命爲該公司的董事,任職日期爲2024年12月18日。弗萊對他在審計和薪酬委員會上的新角色擁有超過35年的投資銀行經驗。他最初的補償包括一份購買42萬股普通股的期權。此外,於2024年11月15日,與詹姆斯·布萊(James Bligh)簽署了一份修訂後的僱傭協議,布萊將繼續擔任臨時首席財務官兼高級副總裁-策略。布萊的協議包括40萬英鎊的年薪和最高可達40%的自由現金獎金。該公司還通過了一項針對其章程的修正案,自2024年年度會議後生效,將股東會議的法定人數由多數改爲至少三分之一的表決權。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息